Bristol-Myers Squibb Company (BMY)
BMY trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$56.67
-1.58% on the day
Market cap
$115.8B
Large cap
Revenue · 2025
$48.2B
-0.2% on 2024
Net income · 2025
$7.1B
14.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | BMY on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000014272 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $48.2B |
| Net income | $7.1B |
| Operating income | Not in SEC XBRL data |
| Net margin | 14.6% |
| Operating margin | Operating income not reported |
| Revenue growth | -0.2% |
| Cash | $10.2B |
| Total assets | $90.0B |
| P/E (computed) | 16.4× |
| P/S (computed) | 2.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-11-07 |
| Latest annual report | 10-K | 2026-02-11 |
| Latest quarterly / interim | 10-Q | 2026-07-30 |
| Latest current report | 8-K | 2026-07-30 |
| Latest proxy | DEFA14A | 2026-04-17 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.9% |
| 1 month | -7.2% |
| 3 months | -2.2% |
| Year to date | +9.7% |
| 1 year | +35.9% |
| From 52-week high | -13.1% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorporated | $485.22 | -4.30% | $123.0B |
| SNY | Sanofi ADS | $39.12 | -1.56% | $95.4B |
| GSK | GSK plc | $46.27 | -1.39% | $93.6B |
| PFE | Pfizer Inc. | $28.37 | -0.11% | $161.7B |
| NVO | Novo Nordisk A/S | $38.06 | -1.35% | $168.5B |
| REGN | Regeneron Pharmaceuticals Inc. | $753.12 | -1.27% | $77.5B |
| ABT | Abbott Laboratories | $102.61 | +0.78% | $177.6B |
| TAK | Takeda Pharmaceutical Company Limited | $18.52 | -0.86% | $58.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier